Table 4. Adverse Events (AEs) by Immune Checkpoint Inhibitor Treatment and Radiation Therapy (RT).
| AE | Treatment group | Patients, No. (%) | ||
|---|---|---|---|---|
| Anti–PD-1a | Anti–PD-1 + anti–CTLA-4b | Anti–PD-L1c | ||
| Colitis | RT≤90 d | 27 (2.4) | 12 (6.1) | 4 (1.1) |
| RT>90 d | 17 (2.5) | NAd | 4 (1.0) | |
| No RT | 182 (2.4) | 100 (11.0) | 52 (1.4) | |
| Diarrhea | RT≤90 d | 269 (24.2) | 93 (47.2) | 86 (23.0) |
| RT>90 d | 145 (21.4) | NAd | 48 (12.2) | |
| No RT | 1915 (25.3) | 453 (49.7) | 515 (13.6) | |
| Endocrine AEs | RT≤90 d | 139 (12.5) | 51 (25.9) | 61 (16.3) |
| RT>90 d | 73 (10.8) | NAd | 32 (8.1) | |
| No RT | 957 (12.6) | 273 (30) | 207 (5.5) | |
| Fatigue | RT≤90 d | 592 (53.3) | 147 (74.6) | 143 (38.2) |
| RT>90 d | 298 (44.1) | NAd | 133 (33.8) | |
| No RT | 3576 (47.3) | 583 (64.0) | 1141 (30.2) | |
| Hepatitis | RT≤90 d | 7 (0.6) | 7 (3.6) | 2 (0.5) |
| RT>90 d | 6 (0.9) | NAd | 1 (0.3) | |
| No RT | 62 (0.8) | 37 (4.1) | 10 (0.3) | |
| Musculoskeletal AEs | RT≤90 d | 13 (1.2) | 4 (2.0) | 7 (1.9) |
| RT>90 d | 8 (1.2) | NAd | 2 (0.5) | |
| No RT | 121 (1.6) | 25 (2.7) | 24 (0.6) | |
| Myocarditis | RT≤90 d | 0 | 1 (0.5) | 0 |
| RT>90 d | 0 | NAd | 0 | |
| No RT | 6 (0.1) | 2 (0.2) | 1 (<0.1) | |
| Neurologic | RT≤90 d | 3 (0.3) | 1 (0.5) | 0 |
| RT>90 d | 2 (0.3) | NAd | 0 | |
| No RT | 14 (0.2) | 2 (0.2) | 5 (0.1) | |
| Neutropenia | RT≤90 d | 21 (1.9) | 5 (2.5) | 10 (2.7) |
| RT>90 d | 5 (0.7) | NAd | 9 (2.3) | |
| No RT | 121 (1.6) | 15 (1.6) | 29 (0.8) | |
| Pneumonitis | RT≤90 d | 47 (4.2) | 19 (9.6) | 51 (13.6) |
| RT>90 d | 22 (3.3) | NAd | 18 (4.6) | |
| No RT | 326 (4.3) | 66 (7.2) | 73 (1.9) | |
| Kidney | RT≤90 d | 3 (0.3) | 2 (1.0) | 1 (0.3) |
| RT>90 d | 0 | NAd | 0 | |
| No RT | 20 (0.3) | 4 (0.4) | 3 (0.1) | |
| Skin AEs | RT≤90 d | 1 (0.1) | 0 | 1 (0.3) |
| RT>90 d | 1 (0.1) | NAd | 1 (0.3) | |
| No RT | 15 (0.2) | 1 (0.1) | 8 (0.2) | |
| Thrombocytopenia | RT≤90 d | 46 (4.1) | 4 (2.0) | 5 (1.3) |
| RT>90 d | 15 (2.2) | NAd | 3 (0.8) | |
| No RT | 163 (2.2) | 29 (3.2) | 47 (1.2) | |
Abbreviations: CTLA-4, cytotoxic T-lymphocyte associated protein 4; NA, not applicable; PD-L1, programmed cell death 1 ligand 1; PD-1, programmed cell death 1.
a
RT≤90 days: n = 1110; RT>90 days: n = 676; no RT: n = 7567.
b
RT≤90 days: n = 197; RT>90 days: n = 15; no RT: n = 911.
c
RT≤90 days: n = 374; RT>90 days: n = 394; no RT: n = 3777.
d
The number of patients in this group was too small for meaningful comparison (n = 15).